MultiCell Technologies Inc (MCET)

[Odessa99]

•••> A $3 billion offer was tendered in 2014 for another biotech company (with minimal recent revenues to boot). Idenix is a 'biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases'. According to their 10-K filing, Idenix only had revenue of $469,000 for all of CY 2013 (see link below for filing), no revenue for Q1 or Q2 of 2014 (according to google finance), and has been bleeding money for several years.

Recently Merck tendered an offer of more than $3 billion to acquire Idenix Pharmaceuticals Inc (because of the patents they own and the research they have conducted.)

So here's an intriguing piece of info... Merck only derived about 3% of its revenue in Q1 2013 from Cancer related drugs. When an industry giant is weak in a particular area, they often use acquisitions to strengthen their weakest areas.

It would seem plausible that a company like Merck, who has already demonstrated their willingness and desire to acquire smaller companies, might eventually be willing to buy a company like MultiCell (for their research performed and patents held). And based upon the $3 billion Merck will be paying for Idenix (with little or no recent revenue), any possible offer could be rich indeed. Could you imagine how an OTC stock would react if Merck expressed some interest in owning them?

As always, simply my opinion.

Merck Completes Tender Offer to Acquire Idenix
http://www.marketwatch.com/story/merck-completes-tender-offer-to-acquire-idenix-2014-08-05

Why Did Merck Pay Such A Huge Premium For Idenix?
http://www.forbes.com/sites/greatspeculations/2014/06/12/why-did-merck-pay-such-a-huge-premium-for-idenix/


Link to Idenix Pharmaceuticals Inc 2013 10-K:
http://www.sec.gov/Archives/edgar/data/1093649/000119312514073142/0001193125-14-073142-index.htm

MCET